Selinexor
- Generic Name
- Selinexor
- Brand Names
- Xpovio 100 Mg Once Weekly Carton, Nexpovio
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11F6N7O
- CAS Number
- 1393477-72-9
- Unique Ingredient Identifier
- 31TZ62FO8F
- Background
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...
- Indication
Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Kari Kendra
- Target Recruit Count
- 8
- Registration Number
- NCT02120222
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- Bhavana Bhatnagar
- Target Recruit Count
- 25
- Registration Number
- NCT02093403
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Selinexor (KPT-330) in Older Patients With Relapsed AML
- Conditions
- Interventions
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 317
- Registration Number
- NCT02088541
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center / University of California, Los Angeles, Los Angeles, California, United States
🇳🇱VU University Medical Center, Amsterdam, Netherlands
🇺🇸Colorado Blood Cancer Institute/Sarah Cannon Research Institute, Denver, Colorado, United States
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
- Conditions
- Interventions
- First Posted Date
- 2014-02-24
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 114
- Registration Number
- NCT02069730
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 116
- Registration Number
- NCT02025985
- Locations
- 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇧🇪UZ Leuven - Universitair Ziekenhuis Leuven, Leuven, Belgium
🇩🇰Rigshospitalet, Copenhagen, Denmark
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 76
- Registration Number
- NCT01986348
- Locations
- 🇩🇰
The Phase I Unit, Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark
🇳🇱University of Groningen Faculty of Medical Sciences, Medical Oncology, Groningen, Netherlands
🇺🇸Dana Farber Cancer Institute, Center for Neuro-Oncology, Boston, Massachusetts, United States
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 192
- Registration Number
- NCT01607905
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇩🇰Rigshospitalet, Copenhagen, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.